Preparation and characterization of solid lipid nanospheres containing paclitaxel

Cavalli, Roberta; Caputo, O.; Gasco, Maria Rosa

doi:10.1016/s0928-0987(00)00081-6

Cited by 115 publications

(55 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cavalli et al found that parenteral administration of nanoparticles of paclitaxel was more bioavailable than an i.v. injection of the plain drug [52] .…”

Section: International Journal Of Pharmaceutical and Life Sciencesmentioning

confidence: 99%

Drug Delivery to The Brain Using Polymeric Nanoparticles: A Review

Bhatt¹,

Ganesh²,

Kothiyal³

2013

Int. J. Pharma Life Sci.

View full text Add to dashboard Cite

Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50-300 nm generally). The use of minute particles as drug carriers for targeted treatment has been studied over a long period of time. A selective accumulation of active substances in target tissues has been demonstrated for certain so-called nanocarrier systems that are administered bound to pharmaceutical drugs. Great expectations are placed on nanocarrier systems that can overcome natural barriers such as the blood-brain barrier (BBB) and transport the medication directly to the desired tissue and thus heal neurological diseases that were formerly incurable. Polymeric Nanoparticle have been shown to be promising carriers for CNS drug delivery due to their potential both in encapsulating drugs, hence protecting them from excretion and metabolism, and in delivering active agents across the blood -brain barrier without inflicting any damage to the barrier. Different polymers have been used and different strategies like surface modification have been done to increase the retention time of nanoparticles.

show abstract

“…Cavalli et al found that parenteral administration of nanoparticles of paclitaxel was more bioavailable than an i.v. injection of the plain drug [52] .…”

Section: International Journal Of Pharmaceutical and Life Sciencesmentioning

confidence: 99%

Drug Delivery to The Brain Using Polymeric Nanoparticles: A Review

Bhatt¹,

Ganesh²,

Kothiyal³

2013

Int. J. Pharma Life Sci.

View full text Add to dashboard Cite

show abstract

“…SLN are able to carry drugs of different structure and lipophilicity, such as cyclosporine A (Ugazio, Cavalli, & Gasco, 2002), paclitaxel (Cavalli, Caputo, & Gasco, 2000), doxorubicin (Fundaro, Cavalli, Bargoni, Vighetto, & Gasco, 2000), tobramycin (Cavalli et al, 2003), shortchain fatty acids AU9 (Dianzani et al, 2006), peptides (Morel, Cavalli, & Gasco, 1996), antisense oligonucleotides (Brioschi et al, 2008), and melatonin (MT) (Rezzani et al, 2009). Also diagnostic compounds such as iron oxides (Pereira, 2003 AU10 ) have been incorporated into SLN.…”

Section: Solid Lipid Nanoparticles From Warm Microemulsionsmentioning

confidence: 99%

Solid lipid nanoparticles and microemulsions for drug delivery

Gasco¹,

Priano

Zara

2009

Nanoneuroscience and Nanoneuropharmacology

Self Cite

View full text Add to dashboard Cite

Abstract:The chapter examined solid lipid nanoparticles (SLN) and microemulsions, chosen as carriers of drugs, administered in vivo to be transported to the central nervous system. Drugs of different structures and for different therapies have been studied such as doxorubicin SLN stealth and nonstealth administered in rats by intravenous route, apomorphine SLN administered in rats by duodenal route, melatonin SLN administered by transdermal and oral routes in humans, and apomorphine microemulsion administered by transdermal route in Parkinson's patients. The pharmacokinetics of the drug, followed in most studies, put in evidence that the many important pharmacokinetic parameters were notably improved versus the drug alone or in a commercial formulation.

show abstract

“…Mice treated with repeated intravenous injections of paclitaxel-loaded nanospheres showed a significant tumor regression and higher survival rates than mice treated with free paclitaxel [106]. Sterically stabilized SLNs were also prepared to prolong the blood circulation time following intravenous administration [107]. Incorporation of paclitaxel into SLNs enhanced paclitaxel cytotoxicity on the human breast adenocarcinoma cell line MCF-7, but not on the human promyelocytic leukemia cell line HL-60 [77].…”

Section: 46mentioning

confidence: 99%

Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment

Serpe

2003

Nanotechnologies for the Life Sciences

View full text Add to dashboard Cite

The sections in this article are Introduction Cancer as Drug Delivery Target Nanoparticles as Anticancer Drug Delivery System Conventional Nanoparticles Sterically Stabilized Nanoparticles Actively Targetable Nanoparticles Routes of Drug Nanoparticles Administration Anticancer Drug Nanoparticles Anthracyclines Reverse of P‐glycoprotein Mediated Multidrug Resistance of Cancer Cells to Doxorubicin Antiestrogens Anti‐metabolites Camptothecins Cisplatin Paclitaxel Miscellaneous Agents Arsenic Trioxide Butyric Acid Cystatins Diethylenetriaminepentaacetic Acid Mitoxantrone Gene Therapy

show abstract

Preparation and characterization of solid lipid nanospheres containing paclitaxel

Cited by 115 publications

References 8 publications

Drug Delivery to The Brain Using Polymeric Nanoparticles: A Review

Drug Delivery to The Brain Using Polymeric Nanoparticles: A Review

Solid lipid nanoparticles and microemulsions for drug delivery

Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment

Contact Info

Product

Resources

About